Lantern Pharma (NASDAQ:LTRN - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Lantern Pharma to post earnings of ($0.53) per share for the quarter.
Lantern Pharma (NASDAQ:LTRN - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.07. During the same period last year, the firm posted ($0.51) earnings per share. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Lantern Pharma Stock Performance
Shares of NASDAQ:LTRN remained flat at $4.99 during midday trading on Friday. The company had a trading volume of 127,249 shares, compared to its average volume of 414,344. Lantern Pharma has a 12-month low of $2.55 and a 12-month high of $6.12. The stock has a market capitalization of $53.79 million, a PE ratio of -2.71 and a beta of 1.60. The firm's fifty day moving average is $3.70 and its 200-day moving average is $3.79.
Insider Activity at Lantern Pharma
In related news, major shareholder Leslie W. Kreis sold 40,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $3.09, for a total value of $123,600.00. Following the completion of the sale, the insider owned 49,957 shares of the company's stock, valued at approximately $154,367.13. This trade represents a 44.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Aaron G.L. Fletcher sold 40,000 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $3.09, for a total value of $123,600.00. Following the completion of the sale, the insider directly owned 49,957 shares of the company's stock, valued at approximately $154,367.13. This represents a 44.47% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 315,700 shares of company stock valued at $1,000,580. Insiders own 7.31% of the company's stock.
About Lantern Pharma
(
Get Free Report)
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
Further Reading
Before you consider Lantern Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantern Pharma wasn't on the list.
While Lantern Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access